Основная статистика
| CIK | 1873835 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Immix Biopharma, Inc.
SEC Filings (Chronological Order)
На этой странице представлен полный хронологический список документов SEC, за исключением документов о собственности, которые мы предоставляем в других местах.
| August 8, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-41159 IMMIX BIOPHARMA, INC. |
|
| June 23, 2025 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 20, 2025 IMMIX BIOPHARMA, INC. |
|
| June 3, 2025 |
Exhibit 1.1 AT THE MARKET OFFERING AGREEMENT Up to $50,000,000 Shares of Common stock June 3, 2025 Citizens JMP Securities, LLC c/o Citizens JMP Securities, LLC 450 Park Avenue, 5th Floor New York, NY 10022 Ladies and Gentlemen: Immix Biopharma, Inc., a corporation organized under the laws of Delaware (the “Company”), confirms its agreement (this “Agreement”) with Citizens JMP Securities, LLC (the |
|
| June 3, 2025 |
Up to $13,450,000 Shares of Common Stock Filed Pursuant to Rule 424(b)(5) Registration No. 333-269100 PROSPECTUS SUPPLEMENT (to the Prospectus dated January 11, 2023) Up to $13,450,000 Shares of Common Stock We have entered into an at the market offering agreement, dated June 3, 2025, or the ATM Agreement, with Citizens JMP Securities, LLC, or Citizens, relating to the offer and sale of shares of our common stock, par value $0.0001 per s |
|
| June 3, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 3, 2025 IMMIX BIOPHARMA, INC. |
|
| May 19, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q/A (Amendment No. 1) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q/A (Amendment No. |
|
| May 19, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin |
|
| May 19, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 1) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-41159 IMMIX BIO |
|
| May 8, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-41159 IMMIX BIOPHARMA, INC. |
|
| May 5, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin |
|
| April 30, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defin |
|
| March 25, 2025 |
Description of the Registrant’s Securities Exhibit 4.4 DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 As of December 31, 2024, Immix Biopharma, Inc. (“the Company”) had one class of security registered under Section 12 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), its common stock, par value $0.0001 per share (the “Common Stock”). Description of |
|
| March 25, 2025 |
Exhibit 19.1 |
|
| March 25, 2025 |
List of Subsidiaries of Immix Biopharma, Inc. Exhibit 21.1 List of Subsidiaries of Immix Biopharma, Inc. Name State/Country of Organization or Incorporation Ownership Interest Immix Biopharma Australia Pty Ltd. Australia 100 % Nexcella, Inc. Delaware 100 %* *On May 20, 2024, Nexcella, was merged (the “Merger”) with and into the Company, with the Company as the surviving corporation. The Merger was effected pursuant to Section 253 of the Delaw |
|
| March 25, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-41159 IMMIX BIOPHARMA, INC. (Exact |
|
| November 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-41159 IMMIX BIOPHARMA, INC. |
|
| August 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-41159 IMMIX BIOPHARMA, INC. |
|
| July 26, 2024 |
Exhibit 99.1 California Institute for Regenerative Medicine Awards Funding for CAR-T NXC-201 U.S. AL Amyloidosis Clinical Trial (NEXICART-2) ● $8 million grant funds development of NXC-201 in relapsed/refractory AL Amyloidosis LOS ANGELES, July 25, 2024 (GLOBE NEWSWIRE) – Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us”, “IMMX”) (Nasdaq: IMMX), a clinical-stage biopharmaceutical company |
|
| July 26, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): July 25, 2024 IMMIX BIOPHARMA, INC. |
|
| July 22, 2024 |
Exhibit 99.2 IMMIX BIOPHARMA, INC. STOCK OPTION GRANT NOTICE AND OPTION AGREEMENT (Amended and Restated 2021 Omnibus Equity Incentive Plan) As a key leader in our business, you are in a position to have significant influence on the performance and success of Immix Biopharma, Inc. (the “Company”). I am pleased to inform you that, in recognition of the role you play in our collective success, you ha |
|
| July 22, 2024 |
As filed with the Securities and Exchange Commission on July 19, 2024 As filed with the Securities and Exchange Commission on July 19, 2024 Registration No. |
|
| July 22, 2024 |
Exhibit 16.1 July 19, 2024 Office of the Chief Accountant Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Ladies and Gentlemen: We have read the comments made regarding us in Item 4.01 of Form 8-K of Immix Biopharma, Inc. dated July 17, 2024, and are in agreement with those statements. /s/ KMJ Corbin & Company LLP Glendora, California |
|
| July 22, 2024 |
Exhibit 99.3 IMMIX BIOPHARMA, INC. RESTRICTED STOCK AWARD GRANT NOTICE (Amended and Restated 2021 Omnibus Equity Incentive Plan) Immix Biopharma, Inc. (the “Company”), pursuant to its Amended and Restated 2021 Omnibus Equity Incentive Plan (the “Plan”), hereby awards to Participant, in consideration for Participant’s past or future services actually or to be rendered to the Company, the number of |
|
| July 22, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): July 17, 2024 IMMIX BIOPHARMA, INC. |
|
| July 22, 2024 |
Exhibit 107 CALCULATION OF FILING FEE TABLE FORM S-8 (Form type) Immix Biopharma, Inc. |
|
| July 22, 2024 |
Exhibit 99.4 IMMIX BIOPHARMA, INC. AMENDED AND RESTATED 2021 OMNIBUS EQUITY INCENTIVE PLAN RESTRICTED STOCK UNIT AWARD GRANT NOTICE Immix Biopharma, Inc., a Delaware corporation, (the “Company”), pursuant to its Amended and Restated 2021 Omnibus Equity Incentive Plan, as amended from time to time (the “Plan”), hereby grants to the holder listed below (the “Participant”), an award of restricted sto |
|
| June 14, 2024 |
Exhibit 10.1 IMMIX BIOPHARMA, INC. AMENDED AND RESTATED 2021 OMNIBUS EQUITY INCENTIVE PLAN Section 1. Purpose of Plan. The name of the Plan is the Immix Biopharma, Inc. Amended and Restated 2021 Omnibus Equity Incentive Plan (the “Plan”). The purposes of the Plan are to (i) provide an additional incentive to selected employees, directors, and independent contractors of the Company or its Affiliate |
|
| June 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 11, 2024 IMMIX BIOPHARMA, INC. |
|
| May 21, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin |
|
| May 20, 2024 |
Unregistered Sales of Equity Securities, Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 20, 2024 IMMIX BIOPHARMA, INC. |
|
| May 20, 2024 |
Exhibit 4.1 CERTIFICATE OF OWNERSHIP AND MERGER MERGING NEXCELLA, INC., a Delaware corporation, WITH AND INTO IMMIX BIOPHARMA, INC., a Delaware corporation Immix Biopharma, Inc., a Delaware corporation (the “Parent”), hereby certifies that: FIRST: The Parent owns at least 90% of the outstanding shares of each class of the stock of Nexcella, Inc., a Delaware corporation (the “Sub”), that, absent Se |
|
| May 9, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-41159 IMMIX BIOPHARMA, INC. |
|
| April 29, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defin |
|
| March 29, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-41159 IMMIX BIOPHARMA, INC. (Exact |
|
| March 29, 2024 |
List of Subsidiaries of Immix Biopharma, Inc. Exhibit 21.1 List of Subsidiaries of Immix Biopharma, Inc. Name State/Country of Organization or Incorporation Ownership Interest Immix Biopharma Australia Pty Ltd. Australia 100 % Nexcella, Inc. Delaware 95 %* *Prior to December 9, 2022, Nexcella, Inc. was a wholly-owned subsidiary of the Company. As of March 2024, Nexcella, Inc. is 95% owned by the Company. |
|
| February 20, 2024 |
Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Immix Biopharma, Inc. |
|
| February 20, 2024 |
As filed with the Securities and Exchange Commission on February 16, 2024 As filed with the Securities and Exchange Commission on February 16, 2024 Registration No. |
|
| February 7, 2024 |
IMMX / Immix Biopharma, Inc. / HIRSCHMAN ORIN Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 IMMIX BIOPHARMA, INC. (Name of Issuer) Common Stock (Title of Class of Securities) 45258H106 (CUSIP Number) February 6, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed ☐ R |
|
| February 7, 2024 |
5,535,055 Shares of Common Stock Filed Pursuant to Rule 424(b)(5) Registration No. 333-269100 PROSPECTUS SUPPLEMENT (to the Prospectus dated January 11, 2023) 5,535,055 Shares of Common Stock We are selling 5,535,055 shares of our common stock. Our common stock is listed on the Nasdaq Capital Market under the symbol “IMMX.” On February 2, 2024, the last reported sales price of our common stock on the Nasdaq Capital Market was $3. |
|
| February 6, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 6, 2024 IMMIX BIOPHARMA, INC. |
|
| February 6, 2024 |
Immix Biopharma Announces Pricing of $15 Million Public Offering of Common Stock Exhibit 99.2 Immix Biopharma Announces Pricing of $15 Million Public Offering of Common Stock LOS ANGELES, February 5, 2024 — Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us” or “IMMX”), a clinical-stage biopharmaceutical company pioneering personalized therapies for oncology and immunology, today announced that it has priced an underwritten public offering of 5,535,055 shares of its com |
|
| February 6, 2024 |
Underwriting Agreement dated as of February 5, 2024 between the Company and Titan Partners Group LLC Exhibit 1.1 5,535,055 SHARES of Common Stock IMMIX BIOPHARMA, INC. UNDERWRITING AGREEMENT February 5, 2024 Titan Partners Group LLC, a division of American Capital Partners, LLC As the Representative of the Several underwriters, if any, named in Schedule I hereto c/o Titan Partners Group LLC, a division of American Capital Partners, LLC 4 World Trade Center, 29th Floor New York, NY 10007 Ladies an |
|
| February 6, 2024 |
Immix Biopharma Announces Proposed Public Offering of Common Stock Exhibit 99.1 February 5, 2024 Immix Biopharma Announces Proposed Public Offering of Common Stock LOS ANGELES, CA, February 5, 2024 — Immix Biopharma, Inc. (Nasdaq: IMMX) (the “Company”), a clinical-stage biopharmaceutical company trailblazing cell therapies in autoimmune disease, today announced that it intends to offer and sell shares of its common stock in an underwritten public offering. All of |
|
| February 5, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 5, 2024 IMMIX BIOPHARMA, INC. |
|
| February 5, 2024 |
SUBJECT TO COMPLETION, DATED FEBRUARY 5, 2024 Filed Pursuant to Rule 424(b)(5) Registration No. 333-269100 This preliminary prospectus supplement relates to an effective registration statement under the Securities Act of 1933, as amended, but the information in this preliminary prospectus supplement is not complete and may be changed. This preliminary prospectus supplement and the accompanying base prospectus are not an offer to sell and are |
|
| November 13, 2023 |
Exhibit 10.6 IMMIX BIOPHARMA, INC. STOCK OPTION GRANT NOTICE AND OPTION AGREEMENT (Amended and Restated 2021 Omnibus Equity Incentive Plan) As a key leader in our business, you are in a position to have significant influence on the performance and success of Immix Biopharma, Inc. (the “Company”). I am pleased to inform you that, in recognition of the role you play in our collective success, you ha |
|
| November 13, 2023 |
Exhibit 10.2 IMMIX BIOPHARMA, INC. POLICY FOR THE RECOVERY OF ERRONEOUSLY AWARDED INCENTIVE-BASED COMPENSATION Adopted by the Board of Directors on November 6, 2023 The Board of Directors (the “Board”) of Immix Biopharma, Inc. (the “Company”) believes that it is in the best interests of the Company and its stockholders to adopt this Policy for the Recovery of Erroneously Awarded Incentive-Based Co |
|
| November 13, 2023 |
Exhibit 10.3 IMMIX BIOPHARMA, INC. STOCK OPTION GRANT NOTICE AND OPTION AGREEMENT (Amended and Restated 2021 Omnibus Equity Incentive Plan) As a key leader in our business, you are in a position to have significant influence on the performance and success of Immix Biopharma, Inc. (the “Company”). I am pleased to inform you that, in recognition of the role you play in our collective success, you ha |
|
| November 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-41159 IMMIX BIOPHARMA, INC. |
|
| November 13, 2023 |
Exhibit 10.5 IMMIX BIOPHARMA, INC. STOCK OPTION GRANT NOTICE AND OPTION AGREEMENT (Amended and Restated 2021 Omnibus Equity Incentive Plan) As a key leader in our business, you are in a position to have significant influence on the performance and success of Immix Biopharma, Inc. (the “Company”). I am pleased to inform you that, in recognition of the role you play in our collective success, you ha |
|
| November 13, 2023 |
Exhibit 10.4 IMMIX BIOPHARMA, INC. STOCK OPTION GRANT NOTICE AND OPTION AGREEMENT (Amended and Restated 2021 Omnibus Equity Incentive Plan) As a key leader in our business, you are in a position to have significant influence on the performance and success of Immix Biopharma, Inc. (the “Company”). I am pleased to inform you that, in recognition of the role you play in our collective success, you ha |
|
| September 26, 2023 |
IMMIX BIOPHARMA, INC. 11400 West Olympic Blvd., Suite 200 Los Angeles, CA 90064 IMMIX BIOPHARMA, INC. 11400 West Olympic Blvd., Suite 200 Los Angeles, CA 90064 VIA EDGAR September 26, 2023 United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, DC 20549 Re: Immix Biopharma, Inc. Acceleration Request for Registration Statement on Form S-3 Filed September 25, 2023 File No. 333-274684 Ladies and Gentlemen: Pursuant to Rule |
|
| September 25, 2023 |
Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Immix Biopharma, Inc. |
|
| September 25, 2023 |
As filed with the Securities and Exchange Commission on September 25, 2023 As filed with the Securities and Exchange Commission on September 25, 2023 No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 IMMIX BIOPHARMA, INC. (Exact name of registrant as specified in its charter) Delaware 45-4869378 (State or other jurisdiction of incorporation) (IRS Employer Identification No.) 1 |
|
| August 30, 2023 |
IMMX / Immix Biopharma Inc / GKCC, LLC - GKCC SCHEDULE 13D Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13D Under the Securities Exchange Act of 1934 IMMIX BIOPHARMA, INC. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 45258H106 (CUSIP Number) GKCC, LLC 501 Silverside Road, Suite 87AVA Wilmington, DE 19809 (302) 992-8882 (Name, Address and Telephone Number of Person Authorized |
|
| August 22, 2023 |
Form of Securities Purchase Agreement dated August 21, 2023 Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is entered into as of August 21, 2023 (the “Effective Date”), by and between Immix Biopharma, Inc., a Delaware corporation (the “Company”), and the subscriber identified on the signature pages hereto (the “Subscriber”). WHEREAS: The Company desires to issue and sell to the Subscriber such number of sha |
|
| August 22, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 22, 2023 IMMIX BIOPHARMA, INC. (Exact name of registrant as specified in its charter) Delaware 001-41159 45-4869378 (State or other jurisdiction of incorporation) (Commission F |
|
| August 22, 2023 |
Form of Pre-Funded Warrant to Purchase Common Stock Exhibit 4.1 PRE-FUNDED WARRANT THESE SECURITIES REPRESENTED HEREBY AND THE SECURITIES ISSUABLE UPON EXERCISE OF THESE SECURITIES HAVE BEEN ACQUIRED FOR INVESTMENT AND HAVE NOT BEEN REGISTERED WITH THE UNITED STATES SECURITIES AND EXCHANGE COMMISSION UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR UNDER ANY APPLICABLE STATE SECURITIES LAWS. WITHOUT SUCH REGISTRATION, SUCH SECURITIES MAY NOT BE SOL |
|
| August 11, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-41159 IMMIX BIOPHARMA, INC. |
|
| July 14, 2023 |
Sales Agreement, dated July 14, 2023, by and between the Company and ThinkEquity LLC Exhibit 1.1 IMMIX BIOPHARMA, INC. Shares of Common Stock ATM Sales Agreement July 14, 2023 ThinkEquity LLC 17 State Street, 41st Floor New York, New York 10004 Ladies and Gentlemen: Immix Biopharma, Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with ThinkEquity LLC (the “Agent”), as follows: 1. Issuance and Sale of Shares. The Company agrees that, from tim |
|
| July 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) July 14, 2023 IMMIX BIOPHARMA, INC. (Exact name of registrant as specified in its charter) Delaware 001-41159 45-4869378 (State or other jurisdiction of incorporation) (Commission File |
|
| July 14, 2023 |
The date of this prospectus supplement is July 14, 2023 TABLE OF CONTENTS Prospectus Supplement Filed pursuant to Rule 424(b)(5) Registration Statement No. 333-269100 PROSPECTUS SUPPLEMENT (To Prospectus Dated January 11, 2023) Up to $4,200,000 Common Stock Immix Biopharma, Inc. We have entered into a sales agreement (the “Sales Agreement”) with ThinkEquity LLC (“ThinkEquity” or the “Sales Agent”), dated July 14, 2023, relating to the sale of shares of our common stock offered by this prospe |
|
| June 13, 2023 |
EX-FILING FEES 4 ex-107.htm Exhibit 107 Calculation of Filing Fee Tables FORM S-8 (Form Type) IMMIX BIOPHARMA, INC. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered (1) Proposed Maximum Offering Price Per Share Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Fee |
|
| June 13, 2023 |
As filed with the Securities and Exchange Commission on June 13, 2023 As filed with the Securities and Exchange Commission on June 13, 2023 Registration No. |
|
| June 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) June 7, 2023 IMMIX BIOPHARMA, INC. (Exact name of registrant as specified in its charter) Delaware 001-41159 45-4869378 (State or other jurisdiction of incorporation) (Commission File |
|
| May 12, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-41159 IMMIX BIOPHARMA, INC. |
|
| May 12, 2023 |
Exhibit 10.2 RE: Employment Agreement – Addendum B May 12, 2023 Further to the Employment Agreement dated June 18, 2021 (the “Agreement”) by and between Immix Biopharma, Inc. (the “Company”) and Ilya Rachman (“Mr. Rachman”), this letter (“Addendum B”) hereby amends as follows: The parties hereby amend Section 3 “Compensation and Benefits” specifically as follows, and not otherwise: 1. Section 3.1 |
|
| May 12, 2023 |
Exhibit 10.3 RE: Management Services Agreement – Addendum C May 12, 2023 Further to the Management Services Agreement dated March 24, 2021 (the “Agreement”) by and between Immix Biopharma, Inc. (the “Company”) and Alwaysraise LLC (“Alwaysraise”), this letter (“Addendum C”) hereby amends as follows: The parties hereby amend Section 4 “Compensation” specifically as follows, and not otherwise: 1. Del |
|
| April 25, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin |
|
| April 25, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defin |
|
| March 27, 2023 |
EX-10.12 3 ex10-12.htm Exhibit 10.12 SENIOR UNSECURED promissory note December 21, 2022 1. Payment Obligation. (a) For value received, the undersigned, Nexcella, Inc. (formerly Immix Biopharma Cell Therapy Inc.), a Delaware corporation (the “Borrower” or the “Company”), unconditionally promises to pay to the order of Immix Biopharma Inc., a Delaware corporation (the “Lender”) the principal amount |
|
| March 27, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-41159 IMMIX BIOPHARMA, INC. (Exact |
|
| March 27, 2023 |
List of Subsidiaries of Immix Biopharma, Inc. Exhibit 21.1 List of Subsidiaries of Immix Biopharma, Inc. Name State/Country of Organization or Incorporation Ownership Interest Immix Biopharma Australia Pty Ltd. Australia 100% Nexcella, Inc. Delaware 98%* *Prior to December 9, 2022, Nexcella, Inc. was a wholly-owned subsidiary of the Company. As of February 2023, Nexcella, Inc. is 98% owned by the Company. |
|
| March 27, 2023 |
Exhibit 4.3 DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 As of December 31, 2022, Immix Biopharma, Inc. (“the Company”) had one class of security registered under Section 12 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), its common stock, par value $0.0001 per share (the “Common Stock”). Description of |
|
| March 22, 2023 |
Sales Agreement, dated March 22, 2023, by and between the Company and ThinkEquity LLC Exhibit 1.1 IMMIX BIOPHARMA, INC. Up to $5,000,000 Shares of Common Stock ATM Sales Agreement March 22, 2023 ThinkEquity LLC 17 State Street, 41st Floor New York, New York 10004 Ladies and Gentlemen: Immix Biopharma, Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with ThinkEquity LLC (the “Agent”), as follows: 1. Issuance and Sale of Shares. The Company agr |
|
| March 22, 2023 |
The date of this prospectus supplement is March 22, 2023 TABLE OF CONTENTS Prospectus Supplement Filed pursuant to Rule 424(b)(5) Registration Statement No. 333-269100 PROSPECTUS SUPPLEMENT (To Prospectus Dated January 11, 2023) Up to $5,000,000 Common Stock Immix Biopharma, Inc. We have entered into a sales agreement (the “Sales Agreement”) with ThinkEquity LLC (“ThinkEquity” or the “Sales Agent”), dated March 22, 2023, relating to the sale of shares of our common stock offered by this prosp |
|
| March 22, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) March 22, 2023 IMMIX BIOPHARMA, INC. (Exact name of registrant as specified in its charter) Delaware 001-41159 45-4869378 (State or other jurisdiction of incorporation) (Commission Fil |
|
| March 13, 2023 |
Regulation FD Disclosure, Entry into a Material Definitive Agreement UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) March 10, 2023 IMMIX BIOPHARMA, INC. (Exact name of registrant as specified in its charter) Delaware 001-41159 45-4869378 (State or other jurisdiction of incorporation) (Commission F |
|
| March 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) March 10, 2023 IMMIX BIOPHARMA, INC. (Exact name of registrant as specified in its charter) Delaware 001-41159 45-4869378 (State or other jurisdiction of incorporation) (Commission Fil |
|
| January 18, 2023 |
Exhibit 10.1 IMMIX BIOPHARMA CELL THERAPY, INC. SHARE PURCHASE AGREEMENT This Share Purchase Agreement (this “Agreement”), is made as of , 2023 by and among Immix Biopharma Cell Therapy, Inc. a Delaware company incorporated with an office at 11400 West Olympic Blvd, Suite 200 Los Angeles, CA 90064 (the “Company”), and the investors listed on Exhibit A attached to this Agreement (each an “Investor” |
|
| January 18, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) January 12, 2023 IMMIX BIOPHARMA, INC. (Exact name of registrant as specified in its charter) Delaware 001-41159 45-4869378 (State or other jurisdiction of incorporation) (Commission F |
|
| January 9, 2023 |
Immix Biopharma, Inc. 11400 West Olympic Blvd., Suite 200 Los Angeles, CA 90064 CORRESP 1 filename1.htm Immix Biopharma, Inc. 11400 West Olympic Blvd., Suite 200 Los Angeles, CA 90064 January 9, 2023 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attention: Lauren Hamill Re: Immix Biopharma, Inc. Registration Statement on Form S-3 File No. 333-269100 Filed January 3, 2023 Ladies and Gentleme |
|
| January 3, 2023 |
Exhibit 107 Calculation of Filing Fee Tables FORM S-3 (Form Type) IMMIX BIOPHARMA, INC. |
|
| January 3, 2023 |
As filed with the U.S. Securities and Exchange Commission on January 3, 2023 As filed with the U.S. Securities and Exchange Commission on January 3, 2023 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Immix Biopharma, Inc. (Exact name of registrant as specified in its charter) Delaware 45-4869378 (State or other jurisdiction IRS Employer of incorporation or organiz |
|
| January 3, 2023 |
Exhibit 4.3 IMMIX BIOPHARMA, INC., ISSUER AND [TRUSTEE], TRUSTEE INDENTURE DATED AS OF , 20 SENIOR DEBT SECURITIES TABLE OF CONTENTS Page ARTICLE I DEFINITIONS 1 Section 1.1 Definitions of Terms 1 ARTICLE II ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 4 Section 2.1 Designation and Terms of Securities 4 Section 2.2 Form of Securities and Trustee?s Certificate 5 Sec |
|
| January 3, 2023 |
EX-4.4 3 ex4-4.htm Exhibit 4.4 IMMIX BIOPHARMA, INC., ISSUER AND [TRUSTEE], TRUSTEE INDENTURE DATED AS OF , 20 SUBORDINATED DEBT SECURITIES TABLE OF CONTENTS Page ARTICLE 1 DEFINITIONS 1 Section 1.01 Definitions of Terms 1 ARTICLE 2 ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 4 Section 2.01 Designation and Terms of Securities 4 Section 2.02 Form of Securities and |
|
| December 16, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) December 16, 2022 IMMIX BIOPHARMA, INC. (Exact name of registrant as specified in its charter) Delaware 001-41159 45-4869378 (State or other jurisdiction of incorporation) (Commission |
|
| December 16, 2022 |
Corporate Presentation of Nexcella, Inc., a wholly-owned subsidiary of Immix Biopharma, Inc. EX-99.1 2 ex99-1.htm Exhibit 99.1 |
|
| December 14, 2022 |
Exhibit 99.1 Immix Biopharma in-licenses NXC-201, BCMA-targeted Next-Generation CAR-T Therapy Demonstrating High Complete Response Rate in Heavily Pre-Treated Multiple Myeloma (71% Complete Responses) and AL Amyloidosis (100% Complete Responses) ? Multiple Myeloma - 85% overall response rate (71% CR/sCR) for NXC-201 at therapeutic dose in an ongoing Phase 1b study in 20 relapsed/refractory patient |
|
| December 14, 2022 |
Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) December 8, 2022 IMMIX BIOPHARMA, INC. (Exact name of registrant as specified in its charter) Delaware 001-41159 45-4869378 (State or other jurisdiction of incorporation) (Commission F |
|
| December 14, 2022 |
EX-10.1 2 ex10-1.htm Exhibit 10.1 [*] Certain information in this document has been omitted from this exhibit because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed RESEARCH AND LICENSE AGREEMENT This Research and License Agreement (this “Agreement”) is entered into on November 27, 2022 (the “Effective Date”), by and between Hadasit Medical Research Servi |
|
| November 9, 2022 |
EX-10.1 2 ex10-1.htm Exhibit 10.1 |
|
| November 9, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-41159 IMMIX BIOPHARMA, INC. |
|
| November 9, 2022 |
Exhibit 10.2 |
|
| August 12, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-41159 IMMIX BIOPHARMA, INC. |
|
| July 19, 2022 |
Immix Biopharma, Inc. 11400 West Olympic Blvd., Suite 200 Los Angeles, CA 90064 RW 1 formrw.htm Immix Biopharma, Inc. 11400 West Olympic Blvd., Suite 200 Los Angeles, CA 90064 July 18, 2022 Securities and Exchange Commission Division of Corporation Finance 100 F Street, NE Washington, D.C. 20549 Re: Immix Biopharma, Inc. File No. 333-265292 Application for Withdrawal on Form RW pursuant to Rule 477 of the Securities Act of 1933 of the Registration Statement on Form S-1 Ladies |
|
| June 30, 2022 |
Immix Biopharma, Inc. 11400 West Olympic Blvd., Suite 200 Los Angeles, CA 90064 RW WD 1 formrwwd.htm Immix Biopharma, Inc. 11400 West Olympic Blvd., Suite 200 Los Angeles, CA 90064 June 30, 2022 Securities and Exchange Commission Division of Corporation Finance 100 F Street, NE Washington, D.C. 20549 Re: Immix Biopharma, Inc. File No. 333-265292 Application for Withdrawal on Form RW pursuant to Rule 477 of the Securities Act of 1933 of the Registration Statement on Form S-1 L |
|
| June 9, 2022 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) June 8, 2022 IMMIX BIOPHARMA, INC. (Exact name of registrant as specified in its charter) Delaware 001-41159 45-4869378 (State or other jurisdiction of incorporation) (Commission File |
|
| May 27, 2022 |
As filed with the U.S. Securities and Exchange Commission on May 27, 2022. As filed with the U.S. Securities and Exchange Commission on May 27, 2022. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 IMMIX BIOPHARMA, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 2834 45-4869378 (State or other jurisdiction of incorporation or organization) ( |
|
| May 27, 2022 |
Form of Representative’s Warrant Exhibit 4.2 THE REGISTERED HOLDER OF THIS PURCHASE WARRANT BY ITS ACCEPTANCE HEREOF, AGREES THAT IT WILL NOT SELL, TRANSFER OR ASSIGN THIS PURCHASE WARRANT EXCEPT AS HEREIN PROVIDED AND THE REGISTERED HOLDER OF THIS PURCHASE WARRANT AGREES THAT IT WILL NOT SELL, TRANSFER, ASSIGN, PLEDGE OR HYPOTHECATE THIS PURCHASE WARRANT FOR A PERIOD OF ONE HUNDRED EIGHTY (180) DAYS FOLLOWING THE EFFECTIVE DATE |
|
| May 27, 2022 |
Form of Underwriting Agreement EX-1.1 2 ex1-1.htm Exhibit 1.1 UNDERWRITING AGREEMENT between IMMIX BIOPHARMA, INC. and THINKEQUITY LLC as Representative of the Several Underwriters IMMIX BIOPHARMA, INC. UNDERWRITING AGREEMENT New York, New York May [●], 2022 ThinkEquity LLC As Representative of the several Underwriters named on Schedule 1 attached hereto 17 State Street, 22nd Fl. New York, NY 10004 Ladies and Gentlemen: The und |
|
| May 27, 2022 | ||
| May 27, 2022 |
EX-FILING FEES 6 ex107.htm CALCULATION OF FILING FEE TABLES Exhibit 107 Calculation of Filing Fee Tables FORM S-1 (Form Type) IMMIX BIOPHARMA, INC. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Share Maximum Aggregate Offering Price((1)(2)(3) F |
|
| May 24, 2022 |
As confidentially submitted to the U.S. Securities and Exchange Commission on May 23, 2022 pursuant to the Jumpstart Our Business Startups Act of 2012. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 IMMIX BIOPHARMA, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 283 |
|
| May 13, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-41159 IMMIX BIOPHARMA, INC. |
|
| April 25, 2022 |
DEFA14A 1 formdefa14a.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by |
|
| April 25, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defin |
|
| March 28, 2022 |
Description of the Registrant’s Securities Exhibit 4.3 DESCRIPTION OF THE REGISTRANT?S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 As of December 31, 2021, Immix Biopharma, Inc. (?the Company?) had one class of security registered under Section 12 of the Securities Exchange Act of 1934, as amended (the ?Exchange Act?), its common stock, par value $0.0001 per share (the ?Common Stock?). Description of |
|
| March 28, 2022 |
Code of Business Conduct and Ethics Exhibit 14.1 IMMIX BIOPHARMA, INC. CODE OF BUSINESS CONDUCT AND ETHICS (Effective September 10, 2021) Immix Biopharma, Inc. (the ?Company?) has adopted the following Code of Business Conduct and Ethics (this ?Code?) for directors, executive officers and employees of the Company. This Code is intended to focus the directors, executive officers and employees on areas of ethical risk, provide guidanc |
|
| March 28, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-41159 IMMIX BIOPHARMA, INC. (Exact |
|
| March 28, 2022 |
List of Subsidiaries of Immix Biopharma, Inc. Exhibit 21.1 List of Subsidiaries of Immix Biopharma, Inc. Name State/Country of Organization or Incorporation Immix Biopharma Australia Pty Ltd. Australia |
|
| March 2, 2022 |
IMMX / Immix Biopharma Inc / Murchinson Ltd. Passive Investment SC 13G/A 1 formsc13ga.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G/A Amendment No. 1 Under the Securities Exchange Act of 1934* Immix Biopharma, Inc. (Name of Issuer) Common Shares, $0.0001 par value (Title of Class of Securities) 45258H106 (CUSIP Number) February 25, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to |
|
| March 2, 2022 |
Joint Filing Statement Pursuant to Rule 13d-1(k)(1) EX-1 2 ex1.htm Exhibit 1 Joint Filing Statement Pursuant to Rule 13d-1(k)(1) The undersigned hereby consent and agree to the joint filing of Schedule 13G under the Securities Exchange Act of 1934, as amended, with respect to the Common Shares of Immix Biopharma, Inc. beneficially owned by them, together with any or all amendments thereto, when and if appropriate. The parties hereto further consent |
|
| February 11, 2022 |
Immix Biopharma, Inc. SC 13G/A EXHIBIT 1 JOINT ACQUISITION STATEMENT PURSUANT TO SECTION 240.13d-1(k) The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G shall be filed on behalf of each of the undersigned without the necessity of filing additional joint |
|
| February 11, 2022 |
IMMX / Immix Biopharma Inc / Altium Capital Management LP - AMENDMENT TO SC 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1 )* Immix Biopharma, Inc. (Name of Issuer) Common stock, $0.0001 par value (Title of Class of Securities) 45258H106 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pu |
|
| February 9, 2022 |
IMMX / Immix Biopharma Inc / Murchinson Ltd. Passive Investment SC 13G 1 formsc13g.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934* Immix Biopharma, Inc. (Name of Issuer) Common Shares, $0.0001 par value (Title of Class of Securities) 45258H106 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule p |
|
| February 9, 2022 |
Joint Filing Statement Pursuant to Rule 13d-1(k)(1) Exhibit 1 Joint Filing Statement Pursuant to Rule 13d-1(k)(1) The undersigned hereby consent and agree to the joint filing of Schedule 13G under the Securities Exchange Act of 1934, as amended, with respect to the Common Shares of Immix Biopharma, Inc. |
|
| January 25, 2022 |
As filed with the Securities and Exchange Commission on January 25, 2022 As filed with the Securities and Exchange Commission on January 25, 2022 Registration No. |
|
| January 19, 2022 |
Exhibit 99.1 ImmixBio Announces Positive IMX-110 Phase 1b/2a Interim Clinical Trial Safety Data Demonstrating 100% Completion of Planned Treatment Cycles ? 100% of patients treated with IMX-110 completed planned treatment cycles without drug-related interruptions in its ongoing Phase 1b/2a clinical trial ? IMX-110 is in clinical development as a monotherapy for soft tissue sarcoma (STS), a $3 bill |
|
| January 19, 2022 |
Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) January 19, 2022 IMMIX BIOPHARMA, INC. (Exact name of registrant as specified in its charter) Delaware 001-41159 45-4869378 (State or other jurisdiction of incorporation) (Commission F |
|
| January 12, 2022 |
EX-99.1 2 ex99-1.htm Exhibit 99.1 ImmixBio IMX-110 Produced 50% Positive Response Rate in First-Line-Therapy-Resistant Cancer, Surpassing the Standard of Care in Mice Study ● IMX-110 produced a 50% response rate after 1 cycle of treatment as a monotherapy in first-line-therapy-resistant cancer - soft tissue sarcoma (STS) mice study ● IMX-110 response rate surpassed standard of care doxorubicin’s r |
|
| January 12, 2022 |
Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) January 12, 2022 IMMIX BIOPHARMA, INC. (Exact name of registrant as specified in its charter) Delaware 001-41159 45-4869378 (State or other jurisdiction of incorporation) (Commission F |
|
| January 3, 2022 |
Exhibit 99.1 U.S. Food and Drug Administration Approves Immix Biopharma Rare Pediatric Disease Designation for IMX-110 as a Treatment for Life-Threatening Pediatric Cancer in Children ? Rare Pediatric Disease Designation (?RPDD?) qualifies Immix Biopharma to receive fast track review, and a priority review voucher (?PRV?) at the time of marketing approval of IMX-110. ? PRV holders can benefit from |
|
| January 3, 2022 |
Other Events, Financial Statements and Exhibits 8-K 1 form8-k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) January 3, 2022 IMMIX BIOPHARMA, INC. (Exact name of registrant as specified in its charter) Delaware 001-41159 45-4869378 (State or other jurisdiction of incorporati |
|
| December 27, 2021 |
EX-1 2 ex-1.htm JOINT ACQUISITION STATEMENT Altium Capital Management, LP SC 13G EXHIBIT 1 JOINT ACQUISITION STATEMENT PURSUANT TO SECTION 240.13d-1(k) The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G shall be filed on behalf of each of the undersigne |
|
| December 27, 2021 |
Altium Capital Management LP - SCHEDULE FILED TO REPORT ACQUISITION OF BENEFICIAL OWNERSHIP SC 13G 1 immx-sc13g121621.htm SCHEDULE FILED TO REPORT ACQUISITION OF BENEFICIAL OWNERSHIP UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Immix Biopharma, Inc. (Name of Issuer) Common stock, $0.0001 par value (Title of Class of Securities) 45258H106 (CUSIP Number) December 16, 2021 (Date of Event Whic |
|
| December 20, 2021 |
8-K 1 form8k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) December 20, 2021 IMMIX BIOPHARMA, INC. (Exact name of registrant as specified in its charter) Delaware 001-41159 45-4869378 (State or other jurisdiction of incorporat |
|
| December 20, 2021 |
Exhibit 3.1 |
|
| December 20, 2021 |
Immix Biopharma, Inc. Announces Closing of Initial Public Offering EX-99.2 5 ex99-2.htm Exhibit 99.2 Immix Biopharma, Inc. Announces Closing of Initial Public Offering LOS ANGELES, CA, Dec. 20, 2021 (GLOBE NEWSWIRE) — Immix Biopharma, Inc. (Nasdaq: IMMX) (“ImmixBio” or the “Company”), a biopharmaceutical company pioneering Tissue Specific Therapeutics (TSTx)TM targeting oncology and immuno-dysregulated diseases, today announced the closing of its initial public o |
|
| December 20, 2021 |
Immix Biopharma, Inc. Announces Pricing of Initial Public Offering Exhibit 99.1 Immix Biopharma, Inc. Announces Pricing of Initial Public Offering December 15, 2021 LOS ANGELES, Dec. 15, 2021 (GLOBE NEWSWIRE) ? Immix Biopharma, Inc. (Nasdaq: IMMX) (?ImmixBio? or the ?Company?), a biopharmaceutical company pioneering Tissue Specific Therapeutics (TSTx)TM targeting oncology and immuno-dysregulated diseases, announced today the pricing of its initial public offering |
|
| December 20, 2021 |
Exhibit 3.2 AMENDED AND RESTATED BYLAWS IMMIX BIOPHARMA, INC. a Delaware Corporation (the ?Corporation?) As Adopted on December 20, 2021 ARTICLE I MEETINGS OF STOCKHOLDERS Section 1.1 Place of Meetings. Meetings of stockholders shall be held at any place, within or outside the State of Delaware, designated by the board of directors of the Corporation (the ?Board of Directors?). The Board of Direct |
|
| December 17, 2021 |
The date of this prospectus is December 15, 2021 PROSPECTUS Filed Pursuant to Rule 424(b)(4) Registration No. 333-259591 4,200,000 Shares Common Stock Immix Biopharma, Inc. This is a firm commitment initial public offering of 4,200,000 shares of Immix Biopharma, Inc. common stock. Prior to this offering, there has been no public market for our common stock. The initial public offering price of our common stock is $5.00 per share. We have been ap |
|
| December 13, 2021 |
8-A12B 1 form8a-12b.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-A FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 Immix Biopharma, Inc. (Exact name of registrant as specified in its charter) Delaware 45-4869378 (State or other jurisdiction of incorporation or organization (I.R.S. Employ |
|
| December 13, 2021 |
IMMIX BIOPHARMA, INC. 1140 West Olympic Blvd., Suite 200 Los Angeles, CA 90064 December 13, 2021 IMMIX BIOPHARMA, INC. 1140 West Olympic Blvd., Suite 200 Los Angeles, CA 90064 December 13, 2021 VIA EDGAR United States Securities and Exchange Commission 100 F. Street, NE Washington, DC 20549 Attention: Gary Newberry Al Pavot Jane Park Laura Crotty Re: Immix Biopharma, Inc. Registration Statement on Form S-1, as amended File No. 333-259591 Ladies and Gentlemen: Pursuant to Rule 461 of the Gener |
|
| December 13, 2021 |
CORRESP 1 filename1.htm December 13, 2021 Via EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, NE Washington, D.C. 20549 Attn: Jane Park Laura Crotty Re: Immix Biopharma, Inc. (the “Company”) Registration Statement on Form S-1/A File No. 333-259591 Acceleration Request Requested Date: December 15, 2021 Requested Time: 4:45 p.m., Eastern Standard Time Ladies an |
|
| December 1, 2021 | ||
| November 4, 2021 |
As filed with the U.S. Securities and Exchange Commission on November 4, 2021. As filed with the U.S. Securities and Exchange Commission on November 4, 2021. Registration No. 333-259591 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 AMENDMENT NO. 4 TO FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 IMMIX BIOPHARMA, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 2834 45-4869378 (State or other jurisdiction of inc |
|
| October 28, 2021 |
Form of Underwriting Agreement Exhibit 1.1 UNDERWRITING AGREEMENT between IMMIX BIOPHARMA, INC. and THINKEQUITY LLC as Representative of the Several Underwriters IMMIX BIOPHARMA, INC. UNDERWRITING AGREEMENT New York, New York [?], 2021 ThinkEquity LLC As Representative of the several Underwriters named on Schedule 1 attached hereto 17 State Street, 22nd Fl. New York, NY 10004 Ladies and Gentlemen: The undersigned, Immix Biophar |
|
| October 28, 2021 |
Form of Representative’s Warrant Exhibit 4.2 Form of Representative?s Warrant Agreement THE REGISTERED HOLDER OF THIS PURCHASE WARRANT BY ITS ACCEPTANCE HEREOF, AGREES THAT IT WILL NOT SELL, TRANSFER OR ASSIGN THIS PURCHASE WARRANT EXCEPT AS HEREIN PROVIDED AND THE REGISTERED HOLDER OF THIS PURCHASE WARRANT AGREES THAT IT WILL NOT SELL, TRANSFER, ASSIGN, PLEDGE OR HYPOTHECATE THIS PURCHASE WARRANT FOR A PERIOD OF ONE HUNDRED EIGH |
|
| October 28, 2021 |
As filed with the U.S. Securities and Exchange Commission on October 28, 2021. As filed with the U.S. Securities and Exchange Commission on October 28, 2021. Registration No. 333-259591 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 AMENDMENT NO. 3 TO FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 IMMIX BIOPHARMA, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 2834 45-4869378 (State or other jurisdiction of inc |
|
| October 15, 2021 |
Exhibit 10.8 [*] Certain information in this document has been omitted from this exhibit because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed. CLINICAL COLLABORATION AND SUPPLY AGREEMENT This Clinical Collaboration and Supply Agreement (this “Agreement”), made as of August 20, 2021 (the “Effective Date”), is by and between IMMiX BioPharma, Inc., a corpo |
|
| October 15, 2021 |
IMMIX BIOPHARMA, INC. 11400 West Olympic Blvd., Suite 200 Los Angeles, CA 90064 IMMIX BIOPHARMA, INC. 11400 West Olympic Blvd., Suite 200 Los Angeles, CA 90064 October 15, 2021 VIA EDGAR United States Securities and Exchange Commission 100 F. Street, NE Washington, DC 20549 Attention: Gary Newberry Al Pavot Jane Park Laura Crotty Re: Immix Biopharma, Inc. Amendment No. 1 to Registration Statement on Form S-1 Filed October 6, 2021 File No. 333-259591 Dear Ladies and Gentlemen: |
|
| October 15, 2021 |
As filed with the U.S. Securities and Exchange Commission on October 15, 2021. As filed with the U.S. Securities and Exchange Commission on October 15, 2021. Registration No. 333-259591 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 AMENDMENT NO. 2 TO FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 IMMIX BIOPHARMA, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 2834 45-4869378 (State or other jurisdiction of inc |
|
| October 6, 2021 |
As filed with the U.S. Securities and Exchange Commission on October 6, 2021. Registration No. 333- 259591 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 AMENDMENT NO. 1 TO FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 IMMIX BIOPHARMA, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 2834 45-4869378 (State or other jurisdiction of inc |
|
| October 6, 2021 |
Form of Indemnification Agreement with directors and executive officers Exhibit 10.2 IMMIX BIOPHARMA, Inc. INDEMNIFICATION AGREEMENT This INDEMNIFICATION AGREEMENT (?Agreement?) is made as of , 2021 by and between Immix Biopharma, Inc., a Delaware corporation (the ?Company?), and (?Indemnitee?). This Agreement supersedes and replaces any and all previous Agreements between the Company and Indemnitee covering the subject matter of this Agreement. RECITALS WHEREAS, high |
|
| October 6, 2021 |
EX-10.1 8 ex10-1.htm Exhibit 10.1 IMMIX BIOPHARMA, INC. 2021 OMNIBUS EQUITY INCENTIVE PLAN Section 1. Purpose of Plan. The name of the Plan is the Immix Biopharma, Inc. 2021 Omnibus Equity Incentive Plan (the “Plan”). The purposes of the Plan are to (i) provide an additional incentive to selected employees, directors, and independent contractors of the Company or its Affiliates whose contributions |
|
| October 6, 2021 |
Second Amended and Restated Certificate of Incorporation, currently in effect Exhibit 3.1 SECOND AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF IMMIX BIOPHARMA, INC. (Pursuant to Sections 242 and 245 of the General Corporation Law of the State of Delaware) Immix Biopharma, Inc., a corporation organized and existing under and by virtue of the provisions of the General Corporation Law of the State of Delaware (the “General Corporation Law”), DOES HEREBY CERTIFY: 1. That |
|
| October 6, 2021 |
Employment Agreement by and between the Company and Ilya Rachman dated June 18, 2021 EX-10.5 12 ex10-5.htm Exhibit 10.5 EMPLOYMENT AGREEMENT AGREEMENT dated as of June 18, 2021 between Ilya Rachman, (“Executive”), and Immix Biopharma, Inc., a Delaware corporation having its principal office at 10573 W. Pico Blvd., # 58, Los Angeles, CA 90064 (“Company”); WHEREAS, the Company desires to employ Executive, and Executive desires to be employed by the Company, on the terms and conditio |
|
| October 6, 2021 |
Exhibit 3.4 IMMIX BIOPHARMA, INC. a Delaware Corporation (the “Corporation”) AMENDED AND RESTATED BYLAWS As Adopted [ ], 2021 ARTICLE I MEETINGS OF STOCKHOLDERS Section 1.1 Place of Meetings. Meetings of stockholders shall be held at any place, within or outside the State of Delaware, designated by the board of directors of the Corporation (the “Board of Directors”). The Board of Directors may, in |
|
| October 6, 2021 |
EX-3.3 4 ex3-3.htm Exhibit 3.3 THIRD AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF IMMIX BIOPHARMA, INC. (Pursuant to Sections 242 and 245 of the General Corporation Law of the State of Delaware) Immix Biopharma, Inc. (the “Corporation”), a corporation organized and existing under and by virtue of the provisions of the General Corporation Law of the State of Delaware (the “DGCL”), does here |
|
| October 6, 2021 |
Exhibit 10.3 Parties and Background [*] Certain information in this document has been omitted from this exhibit because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed. IP Licence Agreement Agreement dated 2017 Parties Licensor Name Immix Biopharma, Inc. Entity Number C3640625 Address 11150 West Olympic Boulevard, Suite 1120, Los Angeles California 90064 U |
|
| October 6, 2021 |
Exhibit 3.2 BYLAWS OF IMMIX BIOPHARMA, INC., a Delaware corporation Adopted as of June 18, 2021 BYLAWS OF IMMIX BIOPHARMA, INC. A DELAWARE CORPORATION ARTICLE I. CORPORATE OFFICES Section 1.1 Registered Office. The board of directors shall establish the registered office of the corporation in the State of Delaware and may, at any time, change the registered office by resolution of the board of dir |
|
| October 6, 2021 |
Certificate of Amendment to Second Amended and Restated Certificate of Incorporation Exhibit 3.5 Certificate of Amendment of Second Amended and Restated Certificate of Incorporation of Immix Biopharma, Inc. Under Section 242 of the Delaware General Corporation Law Immix Biopharma, Inc., a corporation organized and existing under the laws of the State of Delaware (the “Corporation”) hereby certifies as follows: FIRST: The Second Amended and Restated Certificate of Incorporation of |
|
| October 6, 2021 |
Management Services Agreement by and between the Company and Alwaysraise LLC, dated March 18, 2021 Exhibit 10.6 MANAGEMENT SERVICES AGREEMENT This MANAGEMENT SERVICES AGREEMENT (?Agreement?) is made and entered into as of the 24th day of March, 2021 by and between Alwaysraise, LLC, a California limited liability company (?Alwaysraise?), and Immix Biopharma Inc., a Delaware corporation (?Company?) each a ?party? and collectively the ?parties?. WHEREAS, Gabriel Morris (?Mr. Morris?) is the sole p |
|
| October 6, 2021 |
Specimen Stock Certificate evidencing the shares of common stock Exhibit 4.1 |
|
| October 6, 2021 |
IMMIX BIOPHARMA, INC. 11400 West Olympic Blvd., Suite 200 Los Angeles, CA 90064 CORRESP 1 filename1.htm IMMIX BIOPHARMA, INC. 11400 West Olympic Blvd., Suite 200 Los Angeles, CA 90064 October 6, 2021 VIA EDGAR United States Securities and Exchange Commission 100 F. Street, NE Washington, DC 20549 Attention: Gary Newberry Al Pavot Jane Park Laura Crotty Re: Immix Biopharma, Inc. Registration Statement on Form S-1 Filed September 17, 2021 File No. 333-259591 Dear Ladies and Gen |
|
| October 6, 2021 |
Exhibit 10.4 IMMIX BIOPHARMA, INC. 2016 EQUITY INCENTIVE PLAN ADOPTED BY THE BOARD OF DIRECTORS: November 30, 2016 APPROVED BY THE STOCKHOLDERS: November 30, 2016 TERMINATION DATE: November 29, 2026 1. General. (a) Eligible Stock Award Recipients. Employees, Directors and Consultants are eligible to receive Stock Awards. (b) Available Stock Awards. The Plan provides for the grant of the following |
|
| October 6, 2021 |
Master Service Agreement by and between the Company and AxioMx, Inc. dated December 22, 2014 EX-10.7 14 ex10-7.htm Exhibit 10.7 Master Services Agreement This Master Services Agreement (this “Agreement”) dated as of December 22, 2014 (the “Effective Date”) is entered into by and between AxioMx, Inc., a Delaware corporation having a place of business at 688 East Main Street, Branford CT 06405 (“AxioMx”) and Immix Biopharma Inc, a Delaware corporation having an address at 2216 Linnington Av |
|
| September 17, 2021 |
As filed with the U.S. Securities and Exchange Commission on September 16, 2021. S-1 1 forms-1.htm As filed with the U.S. Securities and Exchange Commission on September 16, 2021. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 IMMIX BIOPHARMA, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 2834 45-4869378 (State or other jurisdiction of incorpor |
|
| September 16, 2021 |
IMMIX BIOPHARMA, INC. 11400 West Olympic Blvd., Suite 200 Los Angeles, CA 90064 CORRESP 1 filename1.htm IMMIX BIOPHARMA, INC. 11400 West Olympic Blvd., Suite 200 Los Angeles, CA 90064 September 16, 2021 VIA EDGAR United States Securities and Exchange Commission 100 F. Street, NE Washington, DC 20549 Attention: Gary Newberry Jane Park Laura Crotty Re: Immix Biopharma, Inc. Draft Registration Statement on Form S-1 Submitted July 20, 2021 CIK No. 0001873835 Dear Ladies and Gentl |
|
| July 20, 2021 |
As confidentially submitted to the U.S. Securities and Exchange Commission on July 20, 2021 pursuant to the Jumpstart Our Business Startups Act of 2012. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 IMMIX BIOPHARMA, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 28 |
|
| July 20, 2021 |
DRSLTR 1 filename1.htm Sheppard, Mullin, Richter & Hampton LLP 30 Rockefeller Plaza New York, New York 10112-0015 212.653.8700 main 212.653.8701 fax www.sheppardmullin.com July 20, 2021 CONFIDENTIAL SUBMISSION VIA EDGAR Draft Registration Statement U.S. Securities and Exchange Commission Division of Corporation Finance 100 F. Street, N.E. Washington, D.C. 20549 Re: Immix Biopharma, Inc. Draft Regi |
